Publications by authors named "Justine Kent"

Claim this Profile
B
Burden of EPS in commercial patients with schizophrenia initiating atypical antipsychotics.
Aditi Kadakia, Brenna L Brady, Carole Dembek, G Rhys Williams, Justine M Kent

Am J Manag Care· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression.
Antony Loebel, Kenneth S Koblan, Joyce Tsai, Ling Deng, Maurizio Fava, Justine Kent

J Affect Disord· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population.
Aditi Kadakia, Brenna L Brady, Carole Dembek, G Rhys Williams, Justine M Kent

J Med Econ· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial.
Carlos M Grilo, Susan L McElroy, James I Hudson, Joyce Tsai, Bradford Navia, Justine Kent

CNS Spectr· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial.
Lenard A Adler, Robert Goldman, Seth C Hopkins, Kenneth S Koblan, Justine Kent

Int Clin Psychopharmacol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
Kenneth S Koblan, Justine Kent, Seth C Hopkins, John H Krystal, Hailong Cheng

N Engl J Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study.
Sharon B Wigal, Seth C Hopkins, Kenneth S Koblan, Ann Childress, Justine M Kent

J Atten Disord· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Kasper Recourt, Peter de Boer, Rob Zuiker, Remy Luthringer, Justine Kent

Transl Psychiatry· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Kasper Recourt, Peter de Boer, Rob Zuiker, Remy Luthringer, Justine Kent

Transl Psychiatry· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial.
Robert L Findling, Lenard A Adler, Thomas J Spencer, Robert Goldman, Seth C Hopkins, Justine Kent

J Child Adolesc Psychopharmacol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
Sander Brooks, Gabriël E Jacobs, Peter de Boer, Justine M Kent, Luc Van Nueten

J Psychopharmacol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
Peter De Boer, Wayne C Drevets, Hany Rofael, Peter van der Ark, Justine M Kent

J Psychopharmacol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Yu Sun, Dai Wang, Giacomo Salvadore, Benjamin Hsu, Mark Curran, Justine M Kent

Brain Behav Immun· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Predictive Validity of the DSM-5 Anxious Distress Specifier for Clinical Outcomes in a Large Cohort of Patients With Major Depressive Disorder.
Roxanne Gaspersz, Femke Lamers, Justine M Kent, Aartjan T F Beekman, Johannes H Smit

J Clin Psychiatry· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anxious distress predicts subsequent treatment outcome and side effects in depressed patients starting antidepressant treatment.
Roxanne Gaspersz, Femke Lamers, Justine M Kent, Aartjan T F Beekman, Johannes H Smit

J Psychiatr Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression.
Justine M Kent, Ella Daly, Iva Kezic, Rosanne Lane, Pilar Lim

Prog Neuropsychopharmacol Biol Psychiatry· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Relevance of Sleep Duration: Results from a Cross-Sectional Analysis Using NHANES.
M Soledad Cepeda, Paul Stang, Clair Blacketer, Justine M Kent, Gayle M Wittenberg

J Clin Sleep Med· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder.
Justine M Kent, David Hough, Jaskaran Singh, Keith Karcher, Gahan Pandina

J Child Adolesc Psychopharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
Ion-George Anghelescu, Luc Janssens, Justine Kent, Peter de Boer, Luc Tritsmans

Eur Neuropsychopharmacol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study.
Justine M Kent, Stuart Kushner, Xiaoping Ning, Keith Karcher, Seth Ness

J Autism Dev Disord· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.
Ella J Daly, Justine M Kent, Luc Janssens, John W Newcomer, Gitta Hüsken

Ann Clin Psychiatry· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials.
Srihari Gopal, David Hough, Keith Karcher, Isaac Nuamah, Joseph Palumbo, Justine Kent

J Clin Psychopharmacol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
Mark E Schmidt, Justine M Kent, Ella Daly, Luc Janssens, Nancy Van Osselaer

Eur Neuropsychopharmacol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doubly randomized delayed-start design for enrichment studies with responders or nonresponders.
Qing Liu, Pilar Lim, Jaskaran Singh, David Lewin, Barry Schwab, Justine Kent

J Biopharm Stat· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases.
Larry Alphs, Srihari Gopal, Keith Karcher, Justine Kent, Jennifer Kern Sliwa

Curr Drug Saf· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis